NASDAQ:DNTH Dianthus Therapeutics (DNTH) Stock Price, News & Analysis $93.44 -4.91 (-4.99%) Closing price 04:00 PM EasternExtended Trading$93.54 +0.09 (+0.10%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Dianthus Therapeutics Stock (NASDAQ:DNTH) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Dianthus Therapeutics alerts:Sign Up Key Stats Today's Range$89.78▼$98.5350-Day Range$93.44▼$115.9652-Week Range$32.22▼$117.88Volume1.19 million shsAverage Volume751,907 shsMarket Capitalization$5.12 billionP/E RatioN/ADividend YieldN/APrice Target$129.83Consensus RatingModerate Buy Company Overview Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing antibody-based medicines for complement-mediated diseases. The complement system is part of the immune system, and abnormal activation can contribute to autoimmune and inflammatory disorders. Dianthus is developing therapies designed to selectively inhibit complement activity while offering potentially durable treatment effects. The company’s lead product candidate, DNTH103, is an investigational monoclonal antibody designed to inhibit C1s, a protein involved in the classical complement pathway. DNTH103 is being evaluated for potential use in generalized myasthenia gravis and other complement-mediated neuromuscular and autoimmune conditions. Dianthus is also advancing additional research programs aimed at addressing diseases in which complement activation plays a role. Dianthus became a publicly traded company through a business combination with Magenta Therapeutics in 2023, after which the combined company adopted the Dianthus Therapeutics name and began trading under the symbol DNTH. The company is headquartered in New York and conducts its drug-development activities through clinical research and collaboration with investigators and medical institutions.AI Generated. May Contain Errors. Read More Dianthus Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks46th Percentile Overall ScoreDNTH MarketRank™: Dianthus Therapeutics scored higher than 46% of companies evaluated by MarketBeat, and ranked 548th out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingModerate Buy Consensus RatingDianthus Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.93, and is based on 1 strong buy rating, 13 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialDianthus Therapeutics has a consensus price target of $129.83, representing about 38.9% upside from its current price of $93.44.Amount of Analyst CoverageDianthus Therapeutics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Dianthus Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Dianthus Therapeutics are expected to decrease in the coming year, from ($3.81) to ($4.74) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Dianthus Therapeutics is -22.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Dianthus Therapeutics is -22.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDianthus Therapeutics has a P/B Ratio of 8.19. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Dianthus Therapeutics' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted15.90% of the float of Dianthus Therapeutics has been sold short.Short Interest Ratio / Days to CoverDianthus Therapeutics has a short interest ratio ("days to cover") of 15.31, which indicates bearish sentiment.Change versus previous monthShort interest in Dianthus Therapeutics has recently increased by 0.14%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldDianthus Therapeutics does not currently pay a dividend.Dividend GrowthDianthus Therapeutics does not have a long track record of dividend growth. News and Social Media2.3 / 5News Sentiment0.65 News SentimentDianthus Therapeutics has a news sentiment score of 0.65. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.50 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Dianthus Therapeutics this week, compared to 5 articles on an average week.Search InterestOnly 2 people have searched for DNTH on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Dianthus Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership1.4 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Dianthus Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $29,276,000.00 in company stock.Percentage Held by Insiders3.02% of the stock of Dianthus Therapeutics is held by insiders.Percentage Held by Institutions47.53% of the stock of Dianthus Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Dianthus Therapeutics' insider trading history. Receive DNTH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Dianthus Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. DNTH Stock News HeadlinesInsider Selling: Dianthus Therapeutics (NASDAQ:DNTH) CAO Sells $2,027,600.00 in StockSeptember 21 at 4:09 AM | americanbankingnews.comDianthus Therapeutics (NASDAQ:DNTH) CAO Edward Carr Sells 20,000 SharesSeptember 19, 2026 | insidertrades.comHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - but now he believes he's found something better. This under-the-radar company sits at the intersection of America's two most important industries, including AI, pays massive dividends, and attracted a famous money manager who put 60% of his multi-billion-dollar fund into it. Tilson is revealing the name and ticker symbol completely free - no credit card or email required.September 23 at 1:00 AM | Stansberry Research (Ad)Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Receives Consensus Rating of "Moderate Buy" from BrokeragesSeptember 13, 2026 | americanbankingnews.comDianthus Therapeutics, Inc. (DNTH) Presents at Citigroup's Biopharma Back to School Summit 2026 TranscriptSeptember 9, 2026 | seekingalpha.comDianthus: Hold, Based On Competitor C1s' CIDP Setback And Continued Claseprubart AdvancementSeptember 5, 2026 | seekingalpha.comDianthus (DNTH) Piles Up Clinical Wins While Its Losses WidenSeptember 5, 2026 | finance.yahoo.comDianthus Therapeutics (NASDAQ:DNTH) EVP Simrat Randhawa Sells 23,124 Shares of StockSeptember 4, 2026 | insidertrades.comSee More Headlines DNTH Stock Analysis - Frequently Asked Questions How have DNTH shares performed this year? Dianthus Therapeutics' stock was trading at $41.21 on January 1st, 2026. Since then, DNTH shares have increased by 126.7% and is now trading at $93.44. How were Dianthus Therapeutics' earnings last quarter? Dianthus Therapeutics, Inc. (NASDAQ:DNTH) released its quarterly earnings data on Tuesday, August, 4th. The company reported ($0.90) EPS for the quarter, missing the consensus estimate of ($0.85) by $0.05. The firm earned $0.76 million during the quarter, compared to analysts' expectations of $0.30 million. Dianthus Therapeutics had a negative trailing twelve-month return on equity of 22.53% and a negative net margin of 10,096.95%. When did Dianthus Therapeutics IPO? Dianthus Therapeutics (DNTH) raised $100 million in an initial public offering on Thursday, June 21st 2018. The company issued 6,666,667 shares at $14.00-$16.00 per share. Who are Dianthus Therapeutics' major shareholders? Top institutional shareholders of Dianthus Therapeutics include BlackRock Inc. (7.54%), Wellington Management Group LLP (5.91%), Braidwell LP (1.09%) and Spruce Street Capital LP (0.65%). Insiders that own company stock include Fairmount Funds Management Llc, Marino Garcia, Ryan Savitz, Edward Carr, Simrat Randhawa, Adam M Veness, Simon Read and Anne Mcgeorge. View institutional ownership trends. How do I buy shares of Dianthus Therapeutics? Shares of DNTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Dianthus Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Dianthus Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Netflix (NFLX), Palo Alto Networks (PANW) and Invesco QQQ (QQQ). Company Calendar Last Earnings8/04/2026Today9/23/2026Next Earnings (Estimated)11/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (13m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 DNTH's financial health is in the Green zone, according to TradeSmith. DNTH has been in this zone for over 13 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:DNTH CIK1690585 Webdianthustx.com Phone(929) 999-4055FaxN/AEmployees92Year FoundedN/APrice Target and Rating Average Price Target for Dianthus Therapeutics$129.83 High Price Target$158.00 Low Price Target$98.00 Potential Upside/Downside+38.9%Consensus RatingModerate Buy Rating Score (0-4)2.93 Research Coverage15 Analysts Profitability EPS (Trailing Twelve Months)($4.15) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$162.34 million Net Margins-10,096.95% Pretax Margin-10,096.95% Return on Equity-22.53% Return on Assets-21.55% Debt Debt-to-Equity RatioN/A Current Ratio26.10 Quick Ratio26.10 Sales & Book Value Annual Sales$2.04 million Price / Sales2,510.05 Cash FlowN/A Price / Cash FlowN/A Book Value$11.41 per share Price / Book8.19Miscellaneous Outstanding Shares54,800,000Free Float53,143,000Market Cap$5.12 billion OptionableOptionable Beta1.24 Social Links 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (NASDAQ:DNTH) was last updated on 9/23/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | SponsoredThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...Golden Portfolio | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dianthus Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Dianthus Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
